Alterity Therapeutics Limited, a development-stage biotechnology company, filed a Form 6-K on June 15, 2026, to provide a notification regarding unquoted securities (ATH). The filing serves as a formal update to the Securities and Exchange Commission (SEC) concerning the company's internal security structure, specifica...

Alterity Therapeutics Limited filed a Form 6-K with the SEC on June 15, 2026, reporting a notification of cessation of securities. The filing includes Exhibit 99.1, which details the cessation of specific securities (ATH). The document was signed by Julian Babarczy, the Chairman of the Board. This report is incorporate...

Anfield Energy Inc. has announced a significant milestone in its equipment procurement program with the receipt of the first custom-built underground haul truck from Young's Machine Company. This truck is intended for use at the Velvet-Wood uranium-vanadium mine in Utah, with plans to relocate it to Colorado mines late...

Ascentage Pharma announced seventeen clinical updates for its core assets, olverembatinib and lisaftoclax, at the EHA 2026 Congress. Olverembatinib, a third-generation BCR-ABL1 inhibitor, demonstrated high efficacy in several trials. In the POLARIS-1 Phase III study for newly diagnosed Ph+ ALL, the CR/CRi rate reached ...

This Form 6-K filing from AstraZeneca PLC announces the U.S. Food and Drug Administration (FDA) approval of Truqap (capivasertib) in combination with abiraterone and prednisone. This combination is the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve ...

AXIA Energia S.A. has announced that its Board of Directors has approved the redemption of 576,923 Class “C” preferred shares (PNCs), equivalent to R$30 million, representing 0.0951% of this class of shares. This initial redemption is a pilot program to evaluate the process. Key dates include: June 18, 2026, for B3 rec...

AXIA Energia S.A. has issued a Form 6-K detailing the tax treatment for the redemption of its class "C" preferred shares (PNC). The redemption price is set at R$52.00 per share, based on the closing price of common shares on June 12, 2026. Payment will be made in Brazilian currency on July 7, 2026, with a subsequent pa...

Ms. Cynthia Paul has resigned from her position as a member of Allot Ltd.'s Board of Directors, effective June 15, 2026. Her resignation is attributed to the demands of her other business responsibilities and is not due to any disagreements with the company's management or policies. Ms. Paul has been a board member sin...

Alvotech has notified Jefferies LLC of its decision to suspend and terminate the ATM Prospectus Supplement. This supplement was related to the potential issuance of the Company's ordinary shares under the Open Market Sale Agreement dated June 14, 2024. Alvotech will not issue any further securities under this agreement...

Ascendis Pharma announced positive long-term data from its completed Phase 3 PaTHway Trial of TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism. The Week 182 results, representing three and a half years of treatment, demonstrated sustained efficacy and safety. Key findings include 86% of patients mee...

Banco Bilbao Vizcaya Argentaria, S.A. (BBVA) has executed the third tranche of its share buyback program. Between June 8 and June 12, 2026, BBVA purchased shares totaling 738,512,283.25 Euros, which represents approximately 50.58% of the maximum cash amount allocated for this tranche. This report is filed in compliance...

Bank of Montreal (BMO) announced its intention to redeem all of its $1 billion 1.928% Series K Medium-Term Notes (Non-Viability Contingent Capital (NVCC)) (Subordinated Indebtedness) First Tranche due July 22, 2031. The redemption will take place on July 22, 2026, with the redemption price set at 100% of the principal ...

On June 12, 2026, Belite Bio, Inc. announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy designed to treat Stargardt disease type 1 (STGD1), a rare inherited retinal di...

This report details the appointments and re-appointments to Braskem S.A.’s Statutory Compliance and Audit Committee (CAE) and other advisory committees to the Board of Directors. The CAE will be composed of Ms. Maria Helena Pettersson (Coordinator), Mr. Paulo Roberto Britto Guimarães, Mr. Heraldo Gilberto de Oliveira, ...

Birkenstock Holding plc announced on June 15, 2026, an offering of €900,000,000 in aggregate principal amount of senior notes due 2033 by its indirect wholly-owned subsidiary, Birkenstock Group B.V. & Co. KG. The gross proceeds will be used to redeem outstanding 5.25% Senior Notes due 2029, finance potential share repu...

Blue Gold Limited filed a Form 6-K to provide notice and proxy materials for its 2026 Annual General Meeting of shareholders scheduled for July 13, 2026. The primary agenda item is the re-election of Candice Beaumont as a Class I director to serve until the 2029 annual general meeting. Beaumont has extensive experience...

C21 Investments Inc. and Vireo Growth Inc. have entered into a definitive arrangement agreement whereby Vireo will acquire all of C21's issued and outstanding common shares. This acquisition is expected to expand Vireo's operating footprint in Nevada, adding three leading dispensaries and approximately 104,000 sq. ft. ...

This filing is an SEC Form 6-K, reporting on the month of June 2026 for the Canadian Imperial Bank of Commerce (CIBC). It includes the Board of Directors Mandate as Exhibit 99.1. The mandate outlines the Board's responsibilities, which include overseeing the management of the bank's business and affairs. Key responsibi...

Clearmind Medicine Inc. (Nasdaq: CMND) reported its unaudited condensed interim consolidated financial results for the three and six months ended April 30, 2026. For the six months ended April 30, 2026, the company reported a net loss of $5,902,236, compared to a net loss of $1,855,549 for the same period in 2025. Oper...

This report details the voting results from Collective Mining Ltd.’s Annual and Special Meeting of Holders of Common Shares held on June 15, 2026. The meeting included the election of directors, appointment of auditors, adoption of a new omnibus plan, and approval of unallocated awards under the stock option plan. All ...

Creative Global Technology Holdings Limited held its 2026 Extraordinary General Meeting (EGM) and a Class B Ordinary Shares meeting on June 12, 2026. During the EGM, shareholders approved all matters, including increasing the voting rights of Class B Ordinary Shares from 20 to 100 votes per share, increasing the author...

Cuprina Holdings (Cayman) Limited announced that its subsidiary, Cuprina Pte. Ltd., has received 510(k) clearance from the U.S. FDA for MEDIFLY Maggots™, a medical-grade Lucilia cuprina larvae product for maggot debridement therapy (MDT). This marks the first U.S. FDA clearance for a Lucilia cuprina maggot debridement ...

Dr. Reddy's Laboratories has announced the first-to-market launch of Bosutinib Tablets 400mg in the United States. This generic equivalent of Bosulif® was developed in collaboration with MSN Laboratories, with Dr. Reddy's holding exclusive marketing rights. The launch expands Dr. Reddy's oncology portfolio and aims to ...

Ecopetrol S.A. announced on June 15, 2026, that it has reached a final agreement with the Oil Workers Union (USO) on a new six-year collective bargaining agreement, effective January 1, 2026. The company also entered into 66 final agreements with other labor unions. These agreements include improvements in working cond...

Companhia Paranaense de Energia (COPEL) has entered into a Share Purchase Agreement (SPA) with Gerdau S.A. for the sale of its 23.03% equity interest in Dona Francisca Energética S.A. (DFESA). The transaction is based on an enterprise value of R$ 150.0 million, with the full amount to be paid in a single installment up...